Eye Health Advancements and Ongoing Challenges in Africa

By Crystal Lubbe

October 15, 2024

The article titled “Promising progress on eye health in the African region, but challenges remain” from the World Health Organization (WHO) Regional Office for Africa highlights several key points regarding the current state of eye health in the African region. While there has been notable progress in eye health, significant challenges remain that hinder further advancements.

Progress Made

Despite significant challenges, progress has been made in integrating eye health into primary health care services in African countries. The WHO has recorded a decrease in vision loss due to Vitamin A deficiency, onchocerciasis, and trachoma. These gains are critical for improving overall well-being and reducing the economic burden associated with preventable vision loss.

Challenges

A dire shortage of financial resources and the concentration of scarce human resources in urban areas continue to hinder eye health progress. This results in low community awareness and inadequate access to eye care services. Only 14% of people who need cataract surgery receive it, while more than 80% of those with shortsightedness do not receive treatment. This is in stark contrast to other regions like North America, Australasia, Western Europe, and the Asia-Pacific, where the figures are lower than 10%. The global estimated costs of uncorrected refractive errors and cataracts are significant, amounting to US$14.3 billion annually.

Emerging Challenges

There is a rising trend of eye health challenges related to aging populations, unhealthy lifestyles, and noncommunicable diseases such as diabetic retinopathy and age-related macular degeneration.

WHO’s Current Focus and Initiatives

The WHO is actively supporting countries to integrate eye health services at the primary care level as part of universal health coverage. This includes providing technical support to countries like Ethiopia, Ghana, Niger, Nigeria, Somalia, and Zambia through national situational analyses, strategic plans, and monitoring frameworks. The SPECS 2030 initiative aims to increase the number of people with access to appropriate spectacles, targeting an effective coverage of refractive error (eREC) of 40% by 2030. Liberia and Mozambique have begun implementing this initiative. Furthermore, the WHO has launched a free self-assessment tool called WHOeyes to promote healthy habits and raise eye care awareness. This tool is available in multiple languages and helps check visual acuity while providing educational messaging.

Economic and Social Impact

Good vision significantly impacts overall well-being, academic achievements, and economic growth. Therefore, addressing eye health challenges is crucial for broader societal benefits.

In summary, while there has been progress in reducing certain causes of blindness in Africa, significant challenges persist, including financial and human resource constraints, low community awareness, and emerging eye health issues related to noncommunicable diseases. The WHO is committed to addressing these challenges through various initiatives and support programs aimed at improving eye health in the African region.

Reference url

Recent Posts

NICE Endorses Dupilumab for Eosinophilic COPD Treatment

By HEOR Staff Writer

January 26, 2026

NICE Backs Dupilumab Eosinophilic COPD Option Dupilumab eosinophilic COPD treatment gains momentum as the National Institute for Health and Care Excellence (NICE) final draft guidance recommends dupilumab as an add-on maintenance therap...
Accelerating FAST-EU Clinical Trials
FAST-EU Clinical Trials Launch with 70-Day Target The FAST-EU clinical trials pilot, known as Facilitating and Accelerating Strategic Clinical Trials in the EU, is a one-year voluntary initiative by the
NICE Endorses Talazoparib Enzalutamide for Prostate Cancer Treatment

By HEOR Staff Writer

January 23, 2026

NICE Backs Talazoparib-Enzalutamide for Advanced Prostate Cancer The National Institute for Health and Care Excellence (NICE) has recommended talazoparib enzalutamide prostate cancer treatment, featuring talazoparib (...